The first objective visual acuity test for everyone

Improving vision testing globally

Easy to use for non eyecare professionals and parents

Very scalable solution for large populations and markets

Addressing a large unmet need

Globally, at least 2.2 billion people have vision impairment. In 1 billion – or almost half – of these cases, vision impairment could have been prevented or has yet to be addressed. Vision impairment poses an enormous global financial burden with the annual global costs of productivity losses associated with vision impairment from uncorrected myopia and presbyopia alone estimated to be US$244 billion and US$25.4 billion. Over 50% of the global population is forecast to suffer from myopia by 2050.[1] There are currently not enough Eyecare Practitioners to meet the current and future demand of growing eyecare needs.

[1] Blindness and vision impairment (; Half the world to be short-sighted by 2050: One billion high myopes globally by 2050 – ScienceDaily.

Identifying Vision Problems in Everyone

Objective Acuity Limited ('OAL') aims to have a major impact in disrupting the current way vision testing is undertaken. OAL has developed an objective visual acuity test, to replace existing subjective tests for everyone. Existing subjective tests cannot be undertaken by young children, non-verbal people, and several other groups of adults. The OAL test is also much faster in testing all children and adults saving time and money, while also providing a more accurate measurement earlier in life.

The OA Vision Tester provides the first ever objective software-based visual acuity test. The first test is an Objective Threshold Visual Acuity Test (TVAT) for everyone based on the direct measurement of visual acuity, a functional read-out of how well a person is seeing. The OA Vision Tester can be used to both provide a Threshold Visual Acuity Score, such as 20/20 and screen for visual acuity problems. Our mission is to have the TVAT become the gold standard in visual acuity testing for everyone.

Use cases include:

  • A group of people that cannot undertake existing subjective visual acuity chart tests, such as young children, non-verbal people, people with communication/cognitive difficulties;
  • All adults and children;
  • Clinical studies and monitoring of vision treatments;
  • Screening for visual acuity problems, such as driver’s license testing, sports performance, pre-schools/schools/government vision screening programmes and pharmacies


Optokinetic Nystagmus

Optokinetic nystagmus (OKN) is an involuntary reflex of the eyes that occurs when an individual sees a moving object or pattern. It is well-recognized as a method of assessing visual acuity, but has, to-date, always been a highly subjective process for the detection of gross visual problems. Optokinetic nystagmus is the basis of our new approach to measuring visual acuity.

The OA Vision Tester

  • A person looks the screen from 1.5 metres with one eye covered - each eye is tested separately or binocularly.
  • The test displays a proprietary moving pattern to induce Optokinetic Nystagmus (OKN).
  • OKN is an involuntary eye movement, an indicator of an intact visual pathway.
  • When the eye detects a moving pattern, it generates OKN.
  • Eye tracking system captures the eye movement data which is analysed using OAL's proprietary algorithms.
  • If OKN is present then the person passes the that level. If OKN is not present, then the person fails that level. The test will show a number of different levels and then determine the Threshold Visual Acuity result in real-time, such as 20/20.
  • The test has been correlated to a gold standard visual acuity letter chart.


Proof of Concept Studies

Objective Acuity has completed successful clinical studies in Adults and Children with a prototype system. More recently, we have undertaken a clinical study of our OA Vision Tester in Memphis, USA. The study demonstrated a strong positive correlation between the OA Vision Tester and an ETDRS Visual Acuity Letter Chart in 100 Adults. We also partnered with Regenxbio and completed successful pilot validation studies in children with Batten's Disease.


Intellectual Property

Objective Acuity is prosecuting patents globally covering the OA Vision Tester.

Meet Our Team

We are experienced and diversified in our strength but together we found a sound team.

With extensive experience in research, development and commercialisation we are dedicated to ensure that this exciting innovation gets taken to market.


Adam PodmoreCEO

Adam has over 13 years’ experience in commercialisation, start-up formation and capital raising of medical and health technologies. Adam has had experience in technology commercialisation, attracting foreign direct investment into New Zealand, strategic development and trade promotion. Adam has been involved in business planning, R&D planning raising seed/venture capital and several licensing deals.

Adam PodmoreCEO

Craig BrownCFO

A seasoned CFO, Craig has a proven track record of growing companies and increasing shareholder returns. His experience has been focussed on high tech, fast growth companies, with intellectual property and a unique selling proposition, enabling and navigating companies through start-up and high growth periods. He has worked across a broad range of Bio-tech companies as CFO and / or Company Director. Craig has raise over $140m in funds with start-up companies.

Craig BrownCFO

Dr Benjamin ThompsonCo-Founder & CSO

Ben is a Professor with joint appointments at The University of Auckland, McGill University and University of Waterloo. He brings significant expertise in vision science and in particular the translation of basic science findings to clinical applications.

Professor Benjamin ThompsonCo-Founder & CSO

Mehrdad SangiCo-Founder

Mehrdad has over 10 years of research experience in computer vision, signal processing, and machine learning. Mehrdad received his PhD in Bioengineering from the University of Auckland. Mehrdad provides project leadership and is involved in advanced technology development.

Mehrdad SangiCo-Founder

Dr Jason TuruwhenuaCo-Founder & Advisor

Jason is a senior research fellow at Auckland Bioengineering Institute. He brings significant expertise in development of engineering based methods for use in vision related applications, which has centered to date on simulation of light transport in the eye, measurement of the corneal surface, and image processing techniques for clinical diagnostics.

Dr Jason TuruwhenuaCo-Founder & Advisor

Boaz KonigSenior Software Engineer

Boaz is a designer at heart and always find new developments exciting and relish the challenge to find innovative solutions to problems. He believes that sound architectural design is crucial to the success of any product/system, and therefore the opportunity to be part of a new product development from the start appeals to him.

Board of Directors

Greg SittersChairman

Greg has a distinguished business career spanning more than 40 years. His roles have primarily been in venture investment, executive management, sales and business development, and corporate and professional governance. He has held posts on a number of key industry forums and received many international business awards. Greg has a passion for assisting and investing in disruptive technologies that address some of the world’s major challenges.

Greg SittersChairman

Sabeen ShaikhDirector

Sabeen Shaikh is an executive with nearly two decades of experience in the healthcare industry between corporate and innovation roles. Her leadership ranges between those with large medical device multi-national companies and large businesses to executive roles for scaling healthcare start-ups.

Sabeen ShaikhDirector

Jim MervisDirector

Jim Mervis is a catalyst for success in company development in life sciences and communications. He has an extensive background in securities and commercial transactions, defining and establishing strategic alliances and securing the financial and human resources for corporate growth. Over the last decade, Mr. Mervis played a pivotal role in the structure, finance and management of four of the most notable bio-pharmaceutical start-ups of the period.

Jim MervisDirector

Advisory Board

Dr. Eileen BirchAdvisor

Director, Crystal Charity Ball Paediatric Vision Laboratory

Retina Foundation of the Southwest

Dallas, Texas, US

Dr. Eileen BirchAdvisor

Dr. Mike RepkaAdvisor

Vice Chair for Clinical Practice, Wilmer Eye Institute

Johns Hopkins University

Baltimore, Maryland, US

Dr. Mike RepkaAdvisor

Dr. Paul HarrisAdvisor

1979 O.D.; State University of New York, State College of Optometry.

Before joining the Southern College of Optometry, Dr. Paul Harris was in private practice in Baltimore, MD. Dr. Harris has published a number of articles, including award-winning ones, for the Journal of Optometric Vision Development and the Journal of the American Optometric Association.

Dr. Paul HarrisAdvisor

Our Latest News

Follow our latest developments.

Contact Info

Please contact us.